Using 99mTc-MIBI Scanning for Multiple Myeloma
Author Information
Author(s): EB Tirovola, L Biassoni, KE Britton, N Kaleva, V Kouykin, JS Malpas
Primary Institution: St Bartholomew's Hospital, London, UK
Hypothesis
Can 99mTc-MIBI scanning effectively detect active disease and predict multidrug resistance in multiple myeloma patients?
Conclusion
99mTc-MIBI scanning is a useful tool for investigating multiple myeloma and may help in managing patients with plasma cell disorders.
Supporting Evidence
- 14 out of 21 patients showed increased uptake of 99mTc-MIBI.
- 99mTc-MIBI scanning had a sensitivity of 100% and specificity of 88% when considering drug-resistant cases.
- Patients with active myeloma had positive scans correlating with clinical and biochemical findings.
Takeaway
Doctors used a special scan called 99mTc-MIBI to look for problems in the bones of people with a blood disease called multiple myeloma, and it worked well.
Methodology
Twenty-one patients with multiple myeloma or MGUS were scanned using 99mTc-MIBI, and results were compared with clinical and radiological findings.
Limitations
The study is limited by the small sample size and the potential for false positives and negatives.
Participant Demographics
Patients had a median age of 62 years, with 19 diagnosed with multiple myeloma and 2 with MGUS.
Want to read the original?
Access the complete publication on the publisher's website